Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alnylam Pharmaceuticals

251.15
-7.2000-2.79%
Post-market: 251.150.00000.00%17:28 EDT
Volume:656.36K
Turnover:166.30M
Market Cap:32.75B
PE:-119.69
High:260.00
Open:259.92
Low:250.35
Close:258.35
Loading ...

Alnylam’s Amvuttra approved by FDA in cardiomyopathy

TIPRANKS
·
21 Mar

BRIEF-Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran)

Reuters
·
21 Mar

US FDA approves Alnylam's drug for rare heart condition

Reuters
·
21 Mar

Alnylam Pharmaceuticals Inc - Majority of Patients Expected to Pay $0 in Out-of-Pocket Costs for Amvuttra

THOMSON REUTERS
·
21 Mar

Alnylam Pharmaceuticals- Remains on Track to Proceed With Additional Global Regulatory Submissions for Vutrisiran in 2025

THOMSON REUTERS
·
21 Mar

Alnylam Announces FDA Approval of Amvuttra® (Vutrisiran), the First Rnai Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults With Attr Amyloidosis With Cardiomyopathy (Attr-Cm)

THOMSON REUTERS
·
21 Mar

Alnylam Pharmaceuticals Is Maintained at Neutral by JP Morgan

Dow Jones
·
11 Mar

Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

Business Wire
·
11 Mar

Dr. Phillip A. Sharp Retirement From Alnylam Pharmaceuticals (NasdaqGS:ALNY) Board Announced

Simply Wall St.
·
07 Mar

High Growth Tech Stocks Leading The US Market

Simply Wall St.
·
06 Mar

Alnylam Announces Retirement of Longtime Board Member, DR. Phillip a. Sharp, Company Co-Founder and Industry Luminary

THOMSON REUTERS
·
05 Mar

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

Business Wire
·
05 Mar

Q4 2024 Vir Biotechnology Inc Earnings Call

Thomson Reuters StreetEvents
·
28 Feb

Alnylam Pharmaceuticals: Balancing Promising Pipeline with Competitive Challenges and Strategic Uncertainties

TIPRANKS
·
27 Feb

Alnylam Pharma (ALNY) Receives a Buy from Stifel Nicolaus

TIPRANKS
·
26 Feb

TD Cowen Remains a Buy on Alnylam Pharma (ALNY)

TIPRANKS
·
26 Feb

Alnylam Pharmaceuticals Price Target Maintained With a $320.00/Share by Needham

Dow Jones
·
26 Feb

Cautious Hold on Alnylam Pharmaceuticals Amid Promising Pipeline and Pending Approvals

TIPRANKS
·
26 Feb

Barclays Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

TIPRANKS
·
26 Feb

Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

Business Wire
·
25 Feb